BIOMARKER:

KMT2C mutation

Entrez ID:

Related biomarkers:

‹

›

KMT2C mutation KMT2C mutation	Colorectal Cancer CRC	KMT2C mutation KMT2C mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Solid Tumor Solid Tumor	KMT2C mutation KMT2C mutation	Solid Tumor Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Non Small Cell Lung Cancer NSCLC	KMT2C mutation KMT2C mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Colorectal Cancer CRC	KMT2C mutation KMT2C mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Hepatocellular Cancer HCC	KMT2C mutation KMT2C mutation	Hepatocellular Cancer HCC	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Renal Cell Carcinoma RCC	KMT2C mutation KMT2C mutation	Renal Cell Carcinoma RCC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Melanoma Melanoma	KMT2C mutation KMT2C mutation	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Bladder Cancer Bladder Cancer	KMT2C mutation KMT2C mutation	Bladder Cancer Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials